Mangoceuticals burns 88% of cash in Q1; revenue down 38% as controls disclosure vanishes

Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Cash plummeted from $1.5M to $175K in Q1 2026 (down 88%), driven by operating losses and no new fundraising. Company states it "anticipates the need for additional funding" to sustain operations over the next 12 months.

  MD&A: Liquidity verify on EDGAR →
• high

  Entire disclosure controls and procedures section removed from filing. Prior quarter stated controls were effective; current filing omits required evaluation, raising questions about control status or filing completeness.

  Controls and Procedures verify on EDGAR →
• high

  Revenue fell 38% year-over-year to $68K, attributed to website redevelopment and limited-market testing of new TRT product. Net loss improved $1.4M (30%) via broad expense cuts, but company remains unprofitable.

  MD&A: Results of Operations verify on EDGAR →